Nasopharyngeal Carcinoma Clinical Trials (2026): 142 Recruiting Interventional Studies
Last updated: March 7, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- Immunotherapy + chemoradiotherapy for locally advanced disease (57 Phase 3 trials)
- EBV DNA-guided treatment stratification (reduce treatment for good responders)
- Proton therapy vs photon IMRT (2 Phase 3 trials)
- EBV-targeted CAR-T/TCR-T cell therapy
Standard of care: GP (gemcitabine + cisplatin) induction → concurrent chemoRT → ± adjuvant therapy. Immunotherapy (PD-1 inhibitors) increasingly standard in recurrent/metastatic setting.
Recruiting Trials by Treatment Stage
First-Line Locally Advanced (Curative Intent)
Standard treatment is GP induction + concurrent chemoRT. These trials test immunotherapy additions, radiation optimization, or EBV-guided de-escalation:
- Immunotherapy + standard treatment:
- NCT06712888 - Toripalimab vs Placebo + GP induction (Phase 3)
- NCT04453826 - Camrelizumab + chemoRT vs chemoRT alone (Phase 3)
- NCT06749899 - QL1706 (PD-1/CTLA-4 bispecific) + chemoRT (Phase 3)
- NCT07154069 - Adaptive immunotherapy for NPC (Phase 3)
- Intensified for high-risk (detectable EBV DNA):
- NCT05772208 - Camrelizumab + Nimotuzumab for EBV+ after 1 cycle GP (Phase 3)
- NCT06437627 - TPC + Apatinib + Camrelizumab for high-risk (Phase 3)
- De-escalation for good responders (undetectable EBV DNA):
- NCT05674305 - RT alone vs concurrent chemoRT (Phase 3)
- NCT06092957 - Reduced-dose RT ± CCT for CR after induction (Phase 3)
- NCT04448522 - Reduced vs conventional dose IMRT (Phase 3)
- Proton therapy:
- NCT07340515 - Proton vs Photon IMRT (Phase 3)
- NCT07000643 - Proton vs Photon therapy (Phase 3, non-inferiority)
Recurrent or Metastatic
Immunotherapy + chemotherapy is becoming standard. These trials test new combinations or targets:
- First-line R/M:
- NCT05854849 - Gemcitabine + Camrelizumab + Apatinib vs GP + Cisplatin (Phase 3)
- NCT06176301 - Tislelizumab + GX vs GP (Phase 3)
- NCT06382780 - Tislelizumab + GP or TPC for bone metastasis (Phase 3)
- Second-line+ (after immunotherapy):
- NCT06976190 - MRG003 (ADC) + Pucotenlimab vs chemo (Phase 3)
- NCT06629597 - YL201 vs docetaxel/capecitabine (Phase 3)
- NCT06259721 - Anti-PD1 + Nimotuzumab + Capecitabine (platinum-resistant)
- NCT06676722 - SBRT + Nimotuzumab + Tislelizumab (oligoprogression after IO)
- Oligometastatic:
- NCT04944914 - Camrelizumab + SBRT vs Camrelizumab alone (Phase 3)
- NCT07235319 - Immediate vs salvage locoregional RT (Phase 3)
Locoregional Recurrence
For disease recurring in the nasopharynx/neck after prior treatment:
- Re-irradiation:
- NCT05340491 - ChemoRT + Toripalimab vs ChemoRT alone (Phase 3)
- NCT04453813 - Toripalimab + concurrent chemoRT (Phase 3)
- NCT03907826 - PD-1 antibody + chemoRT for recurrent T3/T4 (Phase 3)
- Surgery + adjuvant:
- NCT04778956 - Toripalimab + surgery vs surgery alone (Phase 3)
- NCT05877872 - Reduced-target vs full-target resection (Phase 3)
- NCT06912711 - Toripalimab + Nimotuzumab neoadjuvant/adjuvant
Novel Approaches
- EBV-targeted cellular therapy:
- ADC (antibody-drug conjugate):
- NCT06976190 - MRG003 (EGFR-ADC) + Pucotenlimab (Phase 3)
- NCT06475300 - BL-B01D1 (EGFR×HER3 bispecific ADC) + PD-1
- NCT06839066 - HLX43 (PD-L1 ADC) for R/M NPC (Phase 2)
- Bispecific antibody:
Showing selected notable trials. View all 142 recruiting interventional trials on ClinicalTrials.gov.
Find NPC Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.
Find Matching Trials
